Department of Gastroenterology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Endocrinology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Clin Mol Hepatol. 2022 Oct;28(4):725-738. doi: 10.3350/cmh.2022.0015. Epub 2022 Mar 14.
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.
非酒精性脂肪性肝病（NAFLD）已成为最常见的慢性肝病，在 2 型糖尿病（T2DM）患者中的全球患病率约为 55%。T2DM、肥胖症和 NAFLD 是三种密切相关的病理状况。此外，T2DM 是导致 NAFLD 更快进展为非酒精性脂肪性肝炎（NASH）、肝硬化和肝细胞癌的最强临床危险因素之一。越来越多的证据表明，新型降糖药物，如过氧化物酶体增殖物激活受体激动剂、胰高血糖素样肽-1 受体激动剂、二肽基肽酶-4 抑制剂或钠-葡萄糖共转运蛋白-2 抑制剂，可能降低 NAFLD 进展的速度。本综述旨在简要总结随机对照试验的最新结果，这些试验测试了新旧降糖药物治疗伴有或不伴有共存 T2DM 的成人 NAFLD 或 NASH 的疗效和安全性。
